Tarsus Pharmaceuticals (TARS) Free Cash Flow (2019 - 2026)

Tarsus Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$25.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 20.35% year-over-year to -$25.6 million in Q1 2026; TTM through Mar 2026 was -$26.6 million, a 60.76% increase from a year earlier, with the FY2025 full-year figure at -$22.3 million, up 73.63% from the prior year.
• Free Cash Flow declined to -$25.6 million in Q1 2026 per TARS's latest filing, from $11.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $18.3 million in Q3 2025 and bottomed at -$38.6 million in Q4 2023.
• The 5-year median for Free Cash Flow is -$21.2 million (2025), against an average of -$17.6 million.
• Across the five-year window, Free Cash Flow slumped 509.84% in 2022 and surged 297.32% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$11.0 million in 2022, then plunged by 250.02% to -$38.6 million in 2023, then surged by 38.55% to -$23.7 million in 2024, then surged by 146.3% to $11.0 million in 2025, then slumped by 333.03% to -$25.6 million in 2026.
• Per Business Quant, the three latest TARS Free Cash Flow figures stand at -$25.6 million (Q1 2026), $11.0 million (Q4 2025), and $18.3 million (Q3 2025).